Alimera Sciences (ALIM) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a hold rating in a research report released on Monday morning.

According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

Several other research analysts have also weighed in on the company. HC Wainwright reissued a buy rating and issued a $5.00 price objective on shares of Alimera Sciences in a research report on Friday, October 27th. Cowen reissued a buy rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. Finally, ValuEngine raised Alimera Sciences from a strong sell rating to a sell rating in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $3.38.

Alimera Sciences (NASDAQ:ALIM) remained flat at $$1.28 during mid-day trading on Monday. The stock had a trading volume of 164,821 shares, compared to its average volume of 139,688. Alimera Sciences has a twelve month low of $1.11 and a twelve month high of $1.72. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71. The stock has a market capitalization of $88.51, a P/E ratio of -4.13 and a beta of 2.15.

An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. boosted its position in Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,300 shares of the biopharmaceutical company’s stock after buying an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned approximately 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. 41.78% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/01/12/alimera-sciences-alim-raised-to-hold-at-zacks-investment-research.html.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Alimera Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alimera Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit